Reducing immune tolerance induced by pd-l1
AssigneeInnovative Cellular Therapeutics, Inc.
InventorZhao Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).
Claims13
A pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the human T cells of the population include human T cells that comprise an isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR), wherein the modified PD-1 and the CAR are expressed as gene products that are separate polypeptides;
- and wherein the modified PD-1 is a dominant negative PD-1.
Dependencies are inferred from the claim text.